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ble complications, it is advisable to always provide coverage with
therapeutic dose of heparin during the critical initial window, then
start with low doses of warfarin, and gradually increase the dose
until the therapeutic range is reached.
Roberto Manfredini, MD
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Massimo Gallerani, MD
Section of Internal Medicine, Gerontology and Geriatrics
Department of Clinical and Experimental Medicine
University of Ferrara
Ferrara, Italy
REFERENCES
1. Allaart CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina
RM, et al. Hereditary protein S deficiency in young adults with arterial
occlusive disease. Thromb Haemost 1990;64:206-10.
2. Esmon CT, Vigano-D’Angelo S, D’Angelo A, Comp PC. Anticoagula-
tion protein C and S. Adv Exp Med Biol 1987;214:47-54.
3. Gallerani M, Manfredini R, Moratelli S. Non-haemorrhagic adverse
reactions of oral anticoagulant therapy. J Cardiol 1995;49:1-7.
4. Gallerani M, Ricci L, Manfredini R, Calò G. Acute thrombosis of
abdominal aorta in a patient undergoing warfarin therapy. Am J Emerg
Med 1995;13:617-8.
5. Beldi G, Bissat A, Eugster T, Gurke L, Stierli P, Huber AR. Mural
thrombus of the aorta in association with homozygous plasminogen
activator inhibitor type 1 (PAI-1)-675(4G) and heterozygous GP Ia
807C/T genotypes. J Vasc Surg 2002;36:632-4.
doi:10.1016/j.jvs.2004.08.017
Reply
We thankDrManfredini and his colleagues for their interest in
this topic and agree with their assessment. The patient we have
described initially presented 2 years previously to another hospital
with deep venous thrombosis and at that time she underwent
anticoagulation therapy with heparin as an inpatient, followed by
transition to warfarin therapy. Her records indicate that the aortic
thrombus (as well as thrombus involving upper extremities) oc-
curred despite concurrent warfarin therapy.
Bruce A. Perler, MD
David A. Bluemke, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, Md
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Regarding “Decreased use of iliac extensions and
reduced graft junctions with software assisted
centerline measurements”
The study by Valazquez et al (J Vasc Surg 2004;40:222-7)
demonstrates that computer-derived centerline measurements al-
low sufficiently precise estimates of endograft fabric length, and
thus endograft sizing can be planned more accurately before
surgery. This results in a lesser requirement for iliac extensions and
endograft junctions in genera,l as compared with the era when the
authors used sizing catheter and calipers for estimating endograft
length.
This was first described by our laboratory in March 20001 in a
study that demonstrated the superior accuracy of our computer-
generated central flowline (centerline) measurements of length
over sizing catheter and caliper measurements. The computer
software program was validated with glass phantoms, with mea-
surements simultaneously carried out with electronic calipers for
length and pyknometry for volume. Since then we have noted that
endografts vary considerable in flexibility and stiffness. For exam-
ple, the Guidant unsupported endograft and our own homemade
polytetrafluoroethylene endograft1 are at the flexible end of the
spectrum, and the less flexible AneuRx endograft is at the stiffer
end. The sizing catheter takes the shortest route (“as the crow
flies”) through the various angulations of the aneurysm from the
proximal to the distal landing site. To confuse matters further, the
stiffness of the sizing catheter is quite different from that of the stiff
endografts. Fabric length calculated by this means is shorter than if
one used the central flow line.
Because of this, using central flowline measurements we select
a slightly longer fabric length when using a flexible endograft than
with a stiffer device. Even so, there is an element of guesswork in
selection of the final fabric length. We concur with Velazquez et al
that computer-generated central flowline measurements are more
accurate and represent a better guide for endograft sizing and
planning.
M. Adiseshiah, FRCS
Consultant Vascular/Endovascular Surgeon
University College London Hospitals
London, England
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We appreciate and thank Dr Adiseshiah for comments offered
in agreement with our recently reported findings.1 We are familiar
with the noted previous study in which phantom glass aneurysms
filled with contrast material were used to validate the accuracy and
feasibility in clinical use of 3-dimensional spiral computed tomog-
raphy angiography for preoperative measurements in planning
endovascular abdominal aortic aneurysm repair (EVAR). In that
work the authors’ specific focus centered on volumetric measure-
ments.2 Their software model of computer-generated centerline
measurements also demonstrated high accuracy in measurement of
length, and was superior to sizing catheters or caliper measure-
ments. These findings are consistent with our currently reported
work in which we used the now commercially available MMS
software (Medical Metrx Solutions), and noted an associated
highly significant decrease in use of iliac extensions.
We agree that the issue of optimal length measurements in the
preoperative planning phase for EVARmay be more complex than
initially thought, and is likely to be affected by endograft-specific
design features that affect endograft flexibility and profile, as well as
patient-specific aneurysm anatomy such as degree of angulation
and tortuosity. As the technology for EVAR evolves, further study
of this subject may be required in efforts to optimize the types of
available computer-assisted software options, taking into account
all potentially important endograft-specific and anatomy-specific
features. The goal would continue to be decreased use of endograft
components and junctions, because these affect cost and expected
long-term durability of EVAR.
Omaida C. Velazquez, MD
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